COVID-19 Treatment Strategy: EU Commission identifies five promising treatment candidates
The EU's COVID-19 treatment strategy is yielding a first result today, with the announcement of the first portfolio of five treatments that may soon be available to treat patients across the EU. Four of these treatments are monoclonal antibodies that are subject to continuous evaluation by the European Medicines Agency. The fifth is an immunosuppressant with a marketing authorization that could be extended to the treatment of covid-19 patients.
French document ( can be translated in the language you want when opened in Google Chrome )
https://ec.europa.eu/commission/presscorner/detail/fr/ip_21_3299
The EU's COVID-19 treatment strategy is yielding a first result today, with the announcement of the first portfolio of five treatments that may soon be available to treat patients across the EU. Four of these treatments are monoclonal antibodies that are subject to continuous evaluation by the European Medicines Agency. The fifth is an immunosuppressant with a marketing authorization that could be extended to the treatment of covid-19 patients.
French document ( can be translated in the language you want when opened in Google Chrome )
https://ec.europa.eu/commission/presscorner/detail/fr/ip_21_3299